CIPLANSECipla Limited· PharmaceuticalsMinimalNeutral
Announced Thu, 14 May · 17:21 IST

Cipla Limited has informed the Exchange about Copy of Newspaper Publication

CIPLA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.6%1-day move
₹1435.00
prior close
₹1436.70
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.0+0.0-0.1-0.1-0.6-1.8-2.4-2.6-2.9-1.1-3.4-3.7+0.1
Up moveDown movePending
AI summary

Cipla Limited published its audited standalone and consolidated financial results for Q4 and full year FY2026 ended 31 March 2026. Standalone Q4 total income rose 18.4% year-on-year to ₹357.47 crore, with net profit after tax jumping 46.4% to ₹38.20 crore and basic EPS at ₹5.04. However, for the full year, standalone net profit after tax declined 19.8% to ₹74.10 crore from ₹92.38 crore in the prior year, despite total income growing 6.7% to ₹1,260.18 crore. Consolidated full year net profit after tax also fell 19.8% to ₹75.83 crore. The results were approved by Cipla's Board on 12 May 2026 and published on 14 May 2026 in Business Standard (English) and Sakal (Marathi), in compliance with SEBI Listing Regulations. Statutory auditors M/s Walker Chandiok & Co LLP issued an unmodified report.

Likely market impact

While Q4 showed strong profit recovery with 46% EPS growth, the full-year profit decline of ~20% despite revenue growth signals margin pressure or higher expenses, which may concern investors. The sharp divergence between Q4 performance and annual performance warrants closer examination of cost trends.